Clinical trial · Interventional
Bevacizumab and Endothelium Dependent Vasodilation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most reported side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab, a monoclonal antibody against vascular endothelial growth factor, hypertension had an overall incidence up to 32%. The increase in blood pressure occurs early in treatment. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. Understanding the pathogenesis of this side effect is essential for optimal treatment with this class of drugs. The primary objective is to explore the effect of bevacizumab infusion on endothelium-dependent vasodilation of forearm resistance arteries.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Endothelial Dysfunction | — | UNRESOLVED | — |
| Hypertension | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acetylcholine | Drug | — | UNRESOLVED |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Nitroprusside | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Acetylcholine
- description
- Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab
- interventionNames
- Drug: Acetylcholine
- Drug: Bevacizumab
- type
- EXPERIMENTAL
- label
- Nitroprusside
- description
- Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab
- interventionNames
- Drug: Nitroprusside
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- Vasomotor response assessed by venous occlusion strain gauge plethysmography
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-50 years old 2. Male 3. Results of serum glucose, lipids and creatinine should be within the laboratory's reference ranges. 4. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations. Exclusion Criteria: 1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients. 2. History of or current abuse of drugs, alcohol or solvents. 3. History of malignant disease. 4. First degree relatives with a history of cancer before the age of 50 5. First degree relatives with a history of premature cardiovascular disease before the age of 50 6. Current use of medication. 7. Clinical evidence of cardiac or pulmonary disease 8. Hypertension ( systole \>140mmHG, diastole \>90mmHg) 9. Diabetes mellitus 10. Smoking 11. Any clinically relevant abnormality on ECG. 12. A history of thrombosis or first degree family members with a history of recurrent thrombosis 13. Inability to understand the nature and extent of the trial and the procedures required. 14. Previous participation in a study with bevacizumab
References
Publications (0)
Data not yet available